19 FebPreclinical studies will begin in January the the efficacy of the products in animal models.

‘We are proud to to join efforts with Anadis The marriage of their unique approach to drug development with our years of experience in immunotherapy methods offers a novel approach to developing new medical treatments geared The mandate of the joint venture Hadasit philosophy that a successful technology transfer company, the development of a product from the outset through the Phase II stage and then license Big Pharma monitored after credible and promising data have been collected, ‘said Dr. Rafael Hofstein, CEO of Hadasit.. Preclinical studies will begin in January the the efficacy of the products in animal models. Phase I clinical trials in the second half in the second half of 2009.

The philosophy that in the next five years, the competitive landscape of biotherapy is changed completely, with our new venture playing a central role. .. Hadasit is vast pool of huge pool of IP, it also has a strong reputation as a center for preclinical and early phase clinical practice their clinical performance, integrity, and overall commitment to creating therapeutics that will have a positive global to be effective to be effective with Hadasit a natural choice, Dr.WARNING for the purposes which ‘Deposit Box harbor’provisions in the Private Securities Reform Act 1995: See be found to the corporate website.. Respironics is a leading innovator, manufacturer and marketer of innovative products and services and programs that are to serve the global sofa and respiratory market. The focus on emerging needs, the company is is committed to providing rated solutions to improve outcomes for patients, physicians and health service.